Filing Flows › Health Care › Marimed (MRMD)
Marimed (MRMD) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Marimed (MRMD) Q2 2026 earnings results →
Q2 2026 Revenue up 6% year over year to $41.9M · 9¢ of every $1 of revenue lost · operating margin 1.0%
Marimed made $41.9M in Q2 2026 (+6% Y/Y): Product sales - retail $23.2M, Product sales - wholesale $18.5M, Other revenue $193K. Operating margin 1.0%, net loss $3.6M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $41.9M in Q2 2026, up 6% year over year and up 6% from the previous quarter. Product sales - retail was the largest line at 55% of revenue. Product sales - wholesale added $1.4M year over year (up 8%), 57% of the total change.
Gross margin was 38.7%, down 1.6 points from Q2 2025. Operating profit was $418K, a 1.0% margin (down 1.6 points year over year). Operating profit fell $598K even though revenue rose $2.4M versus Q2 2025, so costs grew faster than sales. Operating expenses grew 6% against revenue growth of 6%. The quarter ended with a net loss of $3.6M, narrower than the previous quarter's $3.8M loss. Net interest and other expense of $2.0M was the main reason.
Operating cash flow was $2.2M (up 647% year over year). Non-cash charges added back $2.3M of depreciation and amortization and $350K of share-based compensation. Working capital and other items added $3.1M. Capital expenditures of $298K left free cash flow of $1.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $41.9M | +6% | 1.0% | −$3.6M | $2.2M |
| Q1 2026 | 10-Q | May 14, 2026 | $39.5M | +4% | 0.3% | −$3.8M | $949K |
| Q4 2025 | 10-K | Mar 12, 2026 | $41.6M | +7% | -10.9% | −$4.6M | $3.4M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $40.8M | +0.4% | 3.9% | −$2.9M | $2.7M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $39.5M | -2% | 2.9% | −$1.3M | $297K |
| Q1 2025 | 10-Q | May 8, 2025 | $37.9M | -0.1% | -2.2% | −$5.5M | $1.3M |
| Q4 2024 | 10-K | Mar 6, 2025 | $38.9M | +0.1% | -3.6% | −$8.5M | −$413K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Marimed
We are a multi-state cannabis operator (“MSO”) in the United States, headquartered in Norwood, Massachusetts, dedicated to improving lives every day through our high-quality products, our actions, and our values. We develop, own, and manage seed to sale state-licensed, state-of-the-art, regulatory-compliant facilities for the cultivation, production, and dispensing of medicinal and adult-use cannabis. We have created and continue to develop our own brands of premium cannabis flower, concentrates, edibles, and other precision-dosed products utilizing our proprietary strains and formulations. We also license our proprietary brands, in select domestic markets, although licensing revenues are not material to our overall results of operations.
In its own words, from its 10-K, filed Mar 12, 2026.
Marimed against its Medicinal Chemicals & Botanical Products peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +6% against the peers' median +7%. Operating margin: 1.0% against the peers' median 1.0%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| MRMD Marimed | Q2 2026 | $41.9M | +6% | 1.0% |
| CURLF Curaleaf Holdings | Q3 2026 | $353M | +11% | 0.8% |
| TLRY Tilray Brands | Q1 FY27 | $257M | +23% | -9.4% |
| TRLV Trulieve Cannabis | Q3 2026 | $230M | -20% | 18.5% |
| USNA Usana Health Sciences | Q2 2026 | $223M | -5% | -9.0% |
| AAWH Ascend Wellness Holdings | Q2 2026 | $126M | -0.9% | 4.2% |
| CRON Cronos Group | Q3 2026 | $83.9M | +72% | 10.8% |
| CGC Canopy Growth | Q2 FY27 | $71.1M | +20% | -23.1% |
| JUSH Jushi Holdings | Q3 2026 | $70.5M | +7% | 5.0% |
Source: Marimed 10-Q on SEC EDGAR · CIK 1522767 · Medicinal Chemicals & Botanical Products
More on MRMD
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results